Skip to main content

Compugen Shares Spike for Second Time in a Week

NEW YORK (GenomeWeb News) – Shares of Compugen jumped 35 percent in early Monday trade on the Nasdaq after the firm announced that it had a new drug target for multiple epithelial tumors using its Monoclonal Antibody Targets Discovery Platform.

The firm's stock rose $1.42 to $5.50 within the first 20 minutes of the market's open. It was the second such spike in Compugen's stock within the past week.

Last week, its shares rose 62 percent in one day after it announced a deal to screen peptide candidates for three Pfizer drug targets.

Compugen said today that the new drug target, CGEN-671, is a membrane splice variant of CD55, a known drug target for gastric cancer for which monoclonal antibody therapies are in clinical development by others. It said that it has already filed patent applications covering the splice variant and its various therapeutic and diagnostic uses.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.